MeiraGTx Reports First Quarter 2023 Financial and Operational Results
LONDON and NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the first quarter ended March 31, 2023, and provided a corporate update.
Related news for (MGTX)
- 24/7 Market News- MeiraGTx Reports Positive AAV-GAD Study Data
- Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors
- MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
- MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia